17,261 trials
Sickle Cell Disease & Thalassemia
Primary: Safety and Tolerability Will be Measured by Acute NiCord® Infusional Toxicity. — 0; 0; 3; 0 participants
HIV Infections
Primary: Change in the Number of Conserved Elements (CEs) With a CD4 or a CD8 T Cell Response From Week 0 to Week 26 — 0; 0; 0 Number of CEs — p=0.137
Functional Constipation
Primary: Change From Baseline in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Study Intervention Period of Each Cohort — 1.379; 0.621…
Ureteral Obstruction · Flank Pain
Primary: Spontaneous Stone Passage Using Fisher's Exact Test — 8; 5 Participants
Recurrent Malignant Solid Neoplasm · Recurrent Osteosarcoma · Refractory Malignant Solid Neoplasm
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 1 Participants
Chronic Refractory Cough
Primary: Change From Baseline to Week 12 in Awake Objective Cough Frequency — -0.185; -0.192; -0.271; -0.243 coughs per hour (log transformed) — p=0.324
Bladder Cancer
Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants
Covid19
Primary: Clinical Improvement by Day 14 — 61; 51; 18; 21 Participants — p=0.1854
Retinopathy of Prematurity (ROP)
Primary: Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 6 Months Corrected Age (CA) — 0; 0; 12; 19 Participants
Duchenne Muscular Dystrophy
Primary: Number of Unanticipated Grade III or Higher Treatment-Related Toxicities — 0; 0 events
Lung Transplant Rejection
Primary: Number of Participants With a Decrease in Titer of One or More DSA (Either Reduced MFI or Absence of DSA on Same Dilution) — 17 Participants
Nonmalignant Neoplasm · Tuberous Sclerosis · Lymphangioleimyomatosis
Primary: Objective Response Rate — 44.4 percentage of participants
Bladder Cancer
Primary: Proportion of Patients Receiving Complete Induction Course — 0.833 proportion of patients
Lymphoma
Primary: Number of Participants With Time to Progression (TTP) — 42; 4 Participants
Coronavirus · Convalescence
Primary: Efficacy of Treatment at Day 28 as Assessed by Number of Participants Who Develop SARS-Cov-2 Infection — 12; 13 Participants — p=0.42